AR062721A1 - Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla - Google Patents

Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla

Info

Publication number
AR062721A1
AR062721A1 ARP070103983A ARP070103983A AR062721A1 AR 062721 A1 AR062721 A1 AR 062721A1 AR P070103983 A ARP070103983 A AR P070103983A AR P070103983 A ARP070103983 A AR P070103983A AR 062721 A1 AR062721 A1 AR 062721A1
Authority
AR
Argentina
Prior art keywords
prepare
oral administration
compound
pharmaceutical composition
medicinal product
Prior art date
Application number
ARP070103983A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062721(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR062721A1 publication Critical patent/AR062721A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP070103983A 2006-09-12 2007-09-10 Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla AR062721A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82531406P 2006-09-12 2006-09-12

Publications (1)

Publication Number Publication Date
AR062721A1 true AR062721A1 (es) 2008-11-26

Family

ID=38835794

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103983A AR062721A1 (es) 2006-09-12 2007-09-10 Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla

Country Status (16)

Country Link
US (1) US20090285887A1 (enExample)
EP (1) EP2061439A1 (enExample)
JP (1) JP2010502762A (enExample)
KR (1) KR20090052346A (enExample)
CN (1) CN101516355A (enExample)
AR (1) AR062721A1 (enExample)
AU (1) AU2007296311A1 (enExample)
BR (1) BRPI0716234A2 (enExample)
CA (1) CA2662542A1 (enExample)
CL (1) CL2007002618A1 (enExample)
EA (1) EA200970267A1 (enExample)
IL (1) IL197295A0 (enExample)
MX (1) MX2009002669A (enExample)
PE (1) PE20080661A1 (enExample)
TW (1) TW200824723A (enExample)
WO (1) WO2008031782A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2010151745A1 (en) * 2009-06-25 2010-12-29 Elite Laboratories, Inc. Oral dosage forms
IL309564A (en) * 2010-02-25 2024-02-01 Pfizer Preparations containing apixaban
AU2015271995A1 (en) * 2010-02-25 2016-01-21 Bristol-Myers Squibb Holdings Ireland Apixaban formulations
CA2809263A1 (en) * 2010-08-27 2012-03-01 Eleni Dokou Pharmaceutical composition and administrations thereof
JP5937091B2 (ja) 2010-10-15 2016-06-22 ブレイン センティネル インコーポレイテッドＢｒａｉｎ Ｓｅｎｔｉｎｅｌ，Ｉｎｃ． 痙攣の検出装置
EP2554159A1 (en) * 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
EP2819670B1 (en) * 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical Composition and Their Administration
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
EP2854759B1 (en) * 2012-05-24 2019-12-18 ratiopharm GmbH Dosage forms comprising apixaban and matrix former
EP2890366A1 (en) 2012-08-28 2015-07-08 DSM Sinochem Pharmaceuticals Netherlands B.V. Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at least one of them is in the form of mini-tablets
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2017146709A1 (en) * 2016-02-25 2017-08-31 Mylan Inc. A unique high-shear granulation process for improved bioavailability of rivaroxaban
GB201721065D0 (en) * 2017-12-15 2018-01-31 Ondosis Ab Delivery device for drug pellets
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
WO2025150072A1 (en) * 2024-01-13 2025-07-17 Pulse Pharmaceuticals Pvt Ltd A stable oral pro-dispersion formulation and implementations thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3240900A (en) * 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
DE60038097T2 (de) * 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung

Also Published As

Publication number Publication date
US20090285887A1 (en) 2009-11-19
CA2662542A1 (en) 2008-03-20
AU2007296311A1 (en) 2008-03-20
CL2007002618A1 (es) 2008-03-14
PE20080661A1 (es) 2008-06-12
TW200824723A (en) 2008-06-16
JP2010502762A (ja) 2010-01-28
KR20090052346A (ko) 2009-05-25
EA200970267A1 (ru) 2009-08-28
BRPI0716234A2 (pt) 2013-10-15
CN101516355A (zh) 2009-08-26
WO2008031782A1 (en) 2008-03-20
IL197295A0 (en) 2009-12-24
EP2061439A1 (en) 2009-05-27
MX2009002669A (es) 2009-03-24

Similar Documents

Publication Publication Date Title
CL2007002618A1 (es) Composicion farmaceutica de liberacion modificada oral que comprende una pluralidad de mini-comprimidos con un diametro menor que 5 mm y comprendiendo un inhibidor del factor xa dentro de una matriz de uno o mas polimeros; procedimiento de preparacio
CR10349A (es) Tabletas de paracetamol de liberacion rapida
BRPI0606883A2 (pt) composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única
BRPI0508342A (pt) formulações farmacêuticas
UY28330A1 (es) Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
WO2011079239A3 (en) Combination tablet with chewable outer layer
ECSP077242A (es) Formulación de comprimidos de liberación extendida que contiene pramipexol o una sal farmacéuticamente aceptable del mismo, un método para su fabricación y su uso
ME03019B (me) Farmaceutska kompozicija n-[2,4-bis(1,1- dimeтileтil)-5-hidroksifenil]- 1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
CL2007002967A1 (es) Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un
CL2012001404A1 (es) Composicion farmaceutica que comprende microparticulas compresibles recubiertas de farmaco, un recubrimiento de liberacion modificada, enmascarador del sabor, que comprende un polimero insoluble en agua y un recubrimiento compresible con un edulcorante no polimero sobre ella; composicion de tabletas de rapida desintegracion oral; metodo de preparacion.
MX2010005092A (es) Formulaciones farmaceuticas.
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
CL2008002411A1 (es) Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
UY33076A (es) Microcápsulas de fexofenadina y composiciones que las contienen
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR025938A1 (es) Nuevas composiciones farmaceuticas.
BRPI0907414A2 (pt) forma oral de dosagem farmacêutica contendo pelo menos dois medicamentos
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
AR090874A1 (es) Formulacion
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos

Legal Events

Date Code Title Description
FB Suspension of granting procedure